Reiko ShinkuraEditorial on the Research Topic
Mucosal vaccines for the induction of antimicrobial immunoglobulin A
IgA antibodies that work in the mucosa, such as intestinal IgA antibodies, are known to have a wide range of antigen specificities, allowing a single type of antibody to respond to multiple antigens. Note that unlike monomeric IgA found in serum, the intestinal environment harbors dimeric or tetrameric forms of IgA, known as secreted IgA (SIgA).
Recently, many papers have shown that mucosal IgA antibodies can deal with a wider range of variants than IgG antibodies, even against the pandemic SARS-CoV2 experienced. In addition, it has become clear that intestinal IgA antibodies, while recognizing multiple antigens, bind to pathogens selectively, with different effects depending on the type of partner, although the molecular mechanisms are still unclear. However, the importance of IgA antibodies in the control of gut microbiota is attracting increasing attention, especially as it becomes clear that the gut microbiota is strongly associated with many diseases. Moreover, the presence of only small amounts of IgA antibodies in germ-free mice indicates that the production of secretory IgA antibodies is induced by stimulation of the microbiome, an important interaction between the microbe and the host immune system.
This Research Topic has focused on the question of how to strengthen the immunity of the mucosa, which is the portal of entry for pathogens into the body. In particular, research has focused on mucosal vaccines that efficiently induce mucosal IgA antibodies that can block pathogens before they enter the body at the mucosal surface. IgA antibodies are thought to be responsible for the overall balance of the bacterial flora, as they screen for bacteria and keep bad bacteria in check and good ones out. However, the mechanisms underlying the selection of viruses by IgA antibodies remain largely unexplored.
The research contained in this Research Topic is an important area that should continue to be carried out in the fight against pathogens, which is expected to continue in the future.
Hopefully, future research will progress further and deeper to combat the next pandemic.
Author contributions
RS: Writing – original draft.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: mucosal vaccine, immunoglobulin A, mucosal immunity, mucosal adjuvant, pandemic
Citation: Shinkura R (2024) Editorial: Mucosal vaccines for the induction of antimicrobial immunoglobulin A. Front. Immunol. 15:1270600. doi: 10.3389/fimmu.2024.1270600
Received: 01 August 2023; Accepted: 20 February 2024;
Published: 27 February 2024.
Edited and Reviewed by:
Botond Z. Igyártó, Thomas Jefferson University, United StatesCopyright © 2024 Shinkura. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Reiko Shinkura, rshinkura@iqb.u-tokyo.ac.jp